Show simple item record

Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2-advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial

dc.contributor.authorRugo, H. S.en
dc.contributor.authorOliveira, M.en
dc.contributor.authorHowell, Sacha Jen
dc.contributor.authorDalenc, F.en
dc.contributor.authorCortes, J.en
dc.contributor.authorGomez, H. L.en
dc.contributor.authorHu, X. C.en
dc.contributor.authorIwata, H.en
dc.contributor.authorJhaveri, K. L.en
dc.contributor.authorLoibl, S.en
dc.contributor.authorMurillo, S. M.en
dc.contributor.authorOkera, M.en
dc.contributor.authorPark, Y. H.en
dc.contributor.authorSohn, J.en
dc.contributor.authorZhukova, L.en
dc.contributor.authorLogan, J.en
dc.contributor.authorTwomey, K.en
dc.contributor.authorKhatun, M.en
dc.contributor.authorD'Cruz, C. M.en
dc.contributor.authorTurner, N. C.en
dc.date.accessioned2023-10-25T08:48:32Z
dc.date.available2023-10-25T08:48:32Z
dc.date.issued2023en
dc.identifier.citationRugo HS, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez HL, et al. Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2-advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772000178.en
dc.identifier.doi10.1200/JCO.2023.41.16_suppl.1067en
dc.identifier.urihttp://hdl.handle.net/10541/626633
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2023.41.16_suppl.1067en
dc.titleCapivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2-advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trialen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniversity of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Franciscoen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record